Trade Lisata Therapeutics, Inc - LSTA CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.04 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.81 |
| Open | 2.81 |
| 1-Year Change | 30.09% |
| Day's Range | 2.79 - 2.86 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 21, 2024 | 2.81 | -0.08 | -2.77% | 2.89 | 2.91 | 2.76 |
| Nov 20, 2024 | 2.89 | 0.15 | 5.47% | 2.74 | 2.92 | 2.64 |
| Nov 19, 2024 | 2.74 | 0.05 | 1.86% | 2.69 | 2.74 | 2.67 |
| Nov 18, 2024 | 2.70 | 0.03 | 1.12% | 2.67 | 2.78 | 2.67 |
| Nov 15, 2024 | 2.70 | -0.05 | -1.82% | 2.75 | 2.84 | 2.61 |
| Nov 14, 2024 | 2.76 | 0.01 | 0.36% | 2.75 | 2.77 | 2.75 |
| Nov 13, 2024 | 2.77 | -0.08 | -2.81% | 2.85 | 2.87 | 2.75 |
| Nov 12, 2024 | 2.85 | -0.04 | -1.38% | 2.89 | 2.89 | 2.75 |
| Nov 11, 2024 | 2.89 | 0.10 | 3.58% | 2.79 | 2.91 | 2.77 |
| Nov 8, 2024 | 2.89 | 0.09 | 3.21% | 2.80 | 2.89 | 2.75 |
| Nov 7, 2024 | 2.90 | 0.13 | 4.69% | 2.77 | 2.91 | 2.74 |
| Nov 6, 2024 | 2.83 | -0.02 | -0.70% | 2.85 | 2.95 | 2.82 |
| Nov 5, 2024 | 2.86 | 0.07 | 2.51% | 2.79 | 2.86 | 2.76 |
| Nov 4, 2024 | 2.86 | -0.03 | -1.04% | 2.89 | 2.99 | 2.63 |
| Nov 1, 2024 | 3.13 | 0.42 | 15.50% | 2.71 | 3.29 | 2.71 |
| Oct 31, 2024 | 2.77 | 0.00 | 0.00% | 2.77 | 2.81 | 2.76 |
| Oct 30, 2024 | 2.79 | 0.10 | 3.72% | 2.69 | 2.79 | 2.69 |
| Oct 29, 2024 | 2.79 | -0.08 | -2.79% | 2.87 | 2.88 | 2.72 |
| Oct 28, 2024 | 2.87 | 0.00 | 0.00% | 2.87 | 2.94 | 2.87 |
| Oct 25, 2024 | 2.88 | 0.01 | 0.35% | 2.87 | 2.93 | 2.87 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Lisata Therapeutics, Inc Company profile
About Caladrius Biosciences Inc
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies. The Company is developing therapeutics based on the characteristics of naturally occurring CD34+ cells. Its product candidates include CLBS16, the subject of both a positive Phase IIa study and Phase IIb (FREEDOM) study in the United States for the treatment of coronary microvascular dysfunction (CMD); HONEDRA (CLBS12), recipient of SAKIGAKE designation in Japan for the treatment of critical limb ischemia (CLI); CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with pre-dialysis chronic kidney disease (CKD), and OLOGO (CLBS14), which reduces mortality, improves angina and increases exercise capacity in patients with otherwise untreatable angina, the product received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA).
Financial summary
BRIEF: For the 39 weeks ended 30 September 2021, Caladrius Biosciences Inc revenues was not reported. Net loss increased from $2.7M to $20.7M. Higher net loss reflects Research and development increase from $6.1M to $12.9M (expense), Other Selling, gen & admi increase of 18% to $7.7M (expense), Stock-based Compensation in R&D increase from $239K to $643K (expense).
Equity composition
Common Stock $.001 Par, 03/11, 500M auth., 78,564,199 issd. reverse acquisition with Fidelity Medical Services Inc. 08/06, Name changed from Phase III Medical, Inc. 08/07, Exchange changed from OTC to AMEX. 08/07, 1-for-10 reverse stock consolidation. Pref Stock B $0.1 Par, 10,000 issd., 07/13, 1-for-10 reverse sotck split.
| Industry: | Biotechnology & Medical Research (NEC) |
110 Allen Road
Second Floor
07920
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com